Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy

医学 肾细胞癌 内科学 肿瘤科 肾透明细胞癌 联合疗法 靶向治疗 替西罗莫司 PI3K/AKT/mTOR通路 癌症 mTOR抑制剂的发现与发展 细胞凋亡 生物化学 化学
作者
Jeffrey Graham,John Connor Wells,Shaan Dudani,Chun Loo Gan,Frede N. Donskov,Jae‐Lyun Lee,Christian Kollmannsberger,Luis Alfredo Meza,Benoit Beuselinck,Aaron Richard Hansen,Scott A. North,Georg A. Bjarnason,Nicolas Sayegh,Ravindran Kanesvaran,Lori Anne Wood,Sebastién J. Hotte,Rana R. McKay,Toni K. Choueiri,Daniel Y.C. Heng
出处
期刊:European Journal of Cancer [Elsevier BV]
卷期号:171: 124-132 被引量:35
标识
DOI:10.1016/j.ejca.2022.05.002
摘要

Immune checkpoint inhibitors (ICI) have demonstrated impressive activity in metastatic clear-cell renal cell carcinoma (ccRCC) and have become standard treatment options for patients with advanced disease. Data supporting the effectiveness of ICI-based therapy in advanced non-clear cell RCC (nccRCC) is more limited.We performed a retrospective analysis using the International Metastatic RCC Database Consortium (IMDC) to evaluate the outcomes of patients with advanced nccRCC. Patients were classified into three groups based on first-line therapy: ICI-based therapy (monotherapy or combination), vascular endothelial growth factor (VEGF) inhibitor monotherapy, or mammalian target of rapamycin (mTOR) inhibitor monotherapy. The primary outcome was overall survival (OS). Secondary outcomes were time to treatment failure (TTF) and objective response rate (ORR). We used the Kaplan-Meier method to compare OS and TTF between treatment groups and Cox proportional hazards models to adjust for prognostic covariates.We identified a total of 1145 patients with metastatic nccRCC. The most common subtype was papillary RCC (54.9%). For first-line therapy, 74.3% received VEGF monotherapy, 15% received mTOR monotherapy, and 10.7% received ICI-based therapy. Median OS in the ICI group was 28.6 months, versus 16.4 months in the VEGF group and 12.2 months in the mTOR group. Median TTF in the ICI group was 6.9 months, versus 5.0 months in the VEGF group and 3.9 months in the mTOR group. ORR was 27.2% in the ICI group, 14.5% in the VEGF group, and 9% in the mTOR group. After adjusting for the IMDC risk group, histological subtype, and age, the hazard ratio for OS was 0.57 (95% CI 0.42-0.78, p < 0.0001) for ICI versus VEGF and 0.50 (95% CI 0.36-0.71, p < 0.0001) for ICI versus mTOR.In advanced nccRCC, first-line ICI-based treatment appears to be associated with improved OS compared to VEGF and mTOR targeted therapy. These results should be confirmed in prospective randomised trials.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
张丁完成签到,获得积分10
刚刚
1秒前
1秒前
wly发布了新的文献求助10
1秒前
悦yue完成签到,获得积分10
2秒前
2秒前
2秒前
木玄机完成签到,获得积分10
2秒前
温暖砖头发布了新的文献求助10
2秒前
2秒前
weather_clear完成签到,获得积分10
2秒前
锅包又发布了新的文献求助10
2秒前
Tim完成签到 ,获得积分10
2秒前
zzy完成签到,获得积分10
3秒前
cc的应助被zhao采纳,获得10
3秒前
3秒前
3秒前
叉叉发布了新的文献求助10
4秒前
4秒前
lx发布了新的文献求助10
4秒前
科岚完成签到 ,获得积分10
5秒前
zx发布了新的文献求助10
5秒前
科研小白发布了新的文献求助10
5秒前
东起欧发布了新的文献求助10
5秒前
qaa2274278941完成签到,获得积分20
5秒前
TEDDY发布了新的文献求助10
5秒前
科研通AI6.3的应助被tang采纳,获得30
5秒前
大雪纷飞发布了新的文献求助10
5秒前
6秒前
weather_clear发布了新的文献求助10
6秒前
cdercder的应助被小郭采纳,获得10
6秒前
6秒前
6秒前
扬帆起航完成签到,获得积分10
6秒前
zyp发布了新的文献求助10
6秒前
上好佳完成签到,获得积分10
6秒前
冷静汉堡发布了新的文献求助10
7秒前
花生完成签到,获得积分10
7秒前
彭于晏的应助被QQQ采纳,获得10
7秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8174559
求助须知:如何正确求助?哪些是违规求助? 9566586
关于积分的说明 21787112
捐赠科研通 7768831
什么是DOI,文献DOI怎么找? 3431746
关于科研通互助平台的介绍 2555956
邀请新用户注册赠送积分活动 2477100